ArticleClinical rheumatology2026
The risk of neuropathy associated with biological therapy in juvenile idiopathic arthritis children.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the risk of neuropathy induced by biological drugs in children with juvenile idiopathic arthritis, clinically and by electrodiagnosis and ultrasonography. PATIENTS AND
methodsEighty juvenile idiopathic arthritis (JIA) patients were divided into 2 groups: 40 patients under treatment of biologic drugs and conventional disease-modifying antirheumatic drugs (DMARDs) in group I for at least 6 months, and 40 patients under treatment of conventional DMARDs only in group II. Assessment was done using pediatric-modified total neuropathy score (Ped-mTNS), electrodiagnostic (EDX) tests, and nerve ultrasound.
resultsThere was a significant increase in Ped-mTNS, distal latency of peroneal nerve, and latency of tibial F wave and H-reflex, and a significant decrease in conduction velocity of both peroneal and tibial nerves in group I in comparison with group II. A positive correlation was detected between Ped-mTNS, cross-sectional area, and distal motor latency of the peroneal nerve, and between Ped-mTNS and tibial F wave latency, and a negative correlation between motor conduction velocity of the peroneal nerve and Ped-mTNS in group I. Absent H-reflex in 2 cases in group I.
conclusionsDemyelinating peripheral neuropathy can represent a rare adverse event in JIA children treated with biological agents. Key Points • The potential risks associated with biological therapy in JIA patients and the importance of neuropathy screening in these patients. • Nerve ultrasound exhibits lower sensitivity compared to nerve conduction studies for detecting early or subclinical demyelination, as morphological changes may not be apparent on imaging despite measurable functional neurophysiological impairment. • Nerve ultrasound has a complementary role in the diagnosis of peripheral neuropathy, but clinical examination and electrodiagnostic testing remain the actual gold standard for the evaluation of the peripheral nervous system.
Indexed as
Identifiers
42461563What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.